2024.07.05
Publisher：
times
Oseltamivir Dry Suspension (strength: 0.36 g, licensed by Zhejiang Brother Enterprises Holding Co., Ltd.) developed and manufactured in Huayi has been approved for marketing by the NMPA!
Oseltamivir phosphate is a neuraminidase inhibitor (NAI) that selectively inhibits the activity of neuraminidase on the surface of influenza viruses, preventing the release of viruses from infected cells and their invasion into neighboring cells. This inhibition stops the replication and release of progeny virus particles in human cells, making it active against both influenza A and B viruses. Oral oseltamivir phosphate is the first-choice antiviral drug for treating influenza, recommended by both domestic and international guidelines. It effectively shortens the duration of the illness, reduces complications, lowers mortality, and shortens hospitalization time. Additionally, it can be used in conjunction with the influenza vaccine to prevent influenza. Using oseltamivir phosphate for the prophylaxis of influenza is an effective supplementary measure for preventing the flu.
With many years of rich experience in project management and superb technical strength, Huayi has won the trust of customers. We always adhere to high standards and strict requirements to ensure he compliance in the drug manufacturing process and controllable drug quality, meeting the manufacturing needs of our clients. Huayi and Zhejiang Brother cooperate because of the common initial intention and achieve win-win because of deep mutual trust, boosting the product successfully approved by NMPA! Look forward to more exciting cooperation between the two sides in the future.
Over the past eighteen years, Huayi has continuously innovated and dedicated itself to the pharmaceutical field, made substantial investments in manufacturing, provided our clients with high-efficient, high-quality, cost-controllable, and trustworthy R&D and manufacture services to help their products approved and marketed!
